Cancer Research Institute: Trends in Global PD-1/PD-L1 Immunotherapy
November 04, 2019
November 04, 2019
NEW YORK, Nov. 4 -- Cancer Research Institute issued the following news:
The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all cancers, announced today the publication in Nature Reviews Drug Discovery of its newest analysis of the global landscape of PD-1/PD-L1 inhibitor drug development for cancer treatment. The report, titled, "Trends in clinical development of PD-1/PD-L1 inhibitors," . . .
The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all cancers, announced today the publication in Nature Reviews Drug Discovery of its newest analysis of the global landscape of PD-1/PD-L1 inhibitor drug development for cancer treatment. The report, titled, "Trends in clinical development of PD-1/PD-L1 inhibitors," . . .